急性ST段抬高型心肌梗死患者应用沙库巴曲缬沙坦钠片的效果观察及对NT-proBNP、Lp-PLA2的影响  

Curative efficacy and influence of Sacubatrovalsartan Sodium Tablets on N-terminal pro-brain natriuretic peptide and lipoprotein associated phospholipase A2 in patients with acute ST-segment elevation myocardial infarction

作　　者：刘向前[1] 李莉 Liu Xiangqian;Li Li(Department of Cardiology,First People's Hospital of Chuzhou City,Anhui Province,Chuzhou 239000,China)

机构地区：[1]滁州市第一人民医院心内科,滁州239000 [2]滁州市第一人民医院检验科,滁州239000

出　　处：《中国循证心血管医学杂志》2021年第7期844-846,共3页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的探讨沙库巴曲缬沙坦钠片对急性ST段抬高型心肌梗死患者N末端脑钠肽前体(NTproBNP)、脂蛋白相关性磷脂酶A2(Lp-PLA2)的影响。方法选择2018年3月至2019年12月于滁州市第一人民医院接受治疗的急性ST段抬高型心肌梗死患者100例,采用抽签法分为观察组(n=52)和对照组(n=48)。对照组给予贝那普利,观察组给予沙库巴曲缬沙坦钠片治疗。比较两组患者的临床疗效、血清NT-proBNP、Lp-PLA2、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、6 min步行距离、不良心血管事件发生率及不良反应发生情况。结果治疗后,两组患者总有效率比较差异显著(P<0.05);治疗前,两组血清NT-proBNP、Lp-PLA2水平无明显差异;治疗后两组血清NT-proBNP、Lp-PLA2水平均显著降低,且观察组均低于对照组(P<0.05);治疗后两组心功能显著改善,且观察组LVESD、LVEDD水平均低于对照组,LVEF、6 min步行距离均高于对照组(P<0.05);两组患者心力衰竭发生率无显著差异,观察组再发心肌梗死、心绞痛及心律失常发生情况均显著低于对照组,差异显著(P<0.05);两组不良反应总发生率分别为5.77%、22.92%,比较差异显著(P<0.05)。结论急性ST段抬高型心肌梗死患者中应用沙库巴曲缬沙坦钠片效果显优于贝那普利,可有助于改善患者NT-proBNP、Lp-PLA2及心功能。Objective To investigate the influence of Sacubatrovalsartan Sodium Tablets on N-terminal probrain natriuretic peptide(NT-proBNP)and lipoprotein associated phospholipase A2(Lp-PLA2)in patients with acute ST-segment elevation myocardial infarction(STEMI).Methods STEMI patients(n=100)were chosen from the First People’s Hospital of Chuzhou City from Mar.2018 to Dec.2019,and divided randomly into observation group(n=52)and control group(n=48).The control group was treated with benazepril and observation group was treated with Sacubatrovalsartan Sodium Tablets.The clinical efficacy,levels of serum NT-proBNP,Lp-PLA2,left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic inner diameter(LVEDD),left ventricular ejection fraction(LVEF)and 6-minute walk distance(6 MWD),and incidence rate of adverse cardiovascular events and adverse reactions were compared between 2 groups.Results The total effective rate had significant difference in 2 groups after treatment(P<0.05).The levels of NT-proBNP and Lp-PLA2 had no significant difference between 2 groups before treatment and decreased significantly in 2 groups after treatment,and were lower in observation group than those in control group(P<0.05).After treatment,the heart function was significantly improved in 2 groups,and levels of LVESD and LVEDD were lower and LVEF and 6 MWD were higher in observation group than those in control group(P<0.05).The incidence rate of heart failure had no significant difference between 2 groups,and the relapses of myocardial infarction,angina pectoris and arrhythmia were lower in observation group than those in control group(P<0.05).The total incidence rate of adverse reaction was 5.77%in observation group and 22.92%in control group with significant difference(P<0.05).Conclusion The curative effect of Sacubatrovalsartan Sodium Tablets is higher than that of benazepril,and it can improve levels of NT-proBNP,Lp-PLA2 and heart function in STEMI patients.

关 键 词：沙库巴曲缬沙坦钠片 贝那普利 急性ST段抬高型心肌梗死 N末端脑钠肽前体 脂蛋白相关性磷脂酶A2 

分 类 号：R542.22[医药卫生—心血管疾病]